Cargando…
Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination f...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031424/ https://www.ncbi.nlm.nih.gov/pubmed/35455240 http://dx.doi.org/10.3390/vaccines10040491 |
_version_ | 1784692386304098304 |
---|---|
author | Barocci, Simone Orlandi, Chiara Diotallevi, Aurora Buffi, Gloria Ceccarelli, Marcello Vandini, Daniela Carlotti, Eugenio Galluzzi, Luca Rocchi, Marco Bruno Luigi Magnani, Mauro Casabianca, Anna |
author_facet | Barocci, Simone Orlandi, Chiara Diotallevi, Aurora Buffi, Gloria Ceccarelli, Marcello Vandini, Daniela Carlotti, Eugenio Galluzzi, Luca Rocchi, Marco Bruno Luigi Magnani, Mauro Casabianca, Anna |
author_sort | Barocci, Simone |
collection | PubMed |
description | We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19. |
format | Online Article Text |
id | pubmed-9031424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90314242022-04-23 Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination Barocci, Simone Orlandi, Chiara Diotallevi, Aurora Buffi, Gloria Ceccarelli, Marcello Vandini, Daniela Carlotti, Eugenio Galluzzi, Luca Rocchi, Marco Bruno Luigi Magnani, Mauro Casabianca, Anna Vaccines (Basel) Brief Report We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19. MDPI 2022-03-23 /pmc/articles/PMC9031424/ /pubmed/35455240 http://dx.doi.org/10.3390/vaccines10040491 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Barocci, Simone Orlandi, Chiara Diotallevi, Aurora Buffi, Gloria Ceccarelli, Marcello Vandini, Daniela Carlotti, Eugenio Galluzzi, Luca Rocchi, Marco Bruno Luigi Magnani, Mauro Casabianca, Anna Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title_full | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title_fullStr | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title_full_unstemmed | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title_short | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination |
title_sort | evaluation of two-month antibody levels after heterologous chadox1-s/bnt162b2 vaccination compared to homologous chadox1-s or bnt162b2 vaccination |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031424/ https://www.ncbi.nlm.nih.gov/pubmed/35455240 http://dx.doi.org/10.3390/vaccines10040491 |
work_keys_str_mv | AT baroccisimone evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT orlandichiara evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT diotalleviaurora evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT buffigloria evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT ceccarellimarcello evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT vandinidaniela evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT carlottieugenio evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT galluzziluca evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT rocchimarcobrunoluigi evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT magnanimauro evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination AT casabiancaanna evaluationoftwomonthantibodylevelsafterheterologouschadox1sbnt162b2vaccinationcomparedtohomologouschadox1sorbnt162b2vaccination |